Morepen Laboratories Limited
2,998words
13turns
0analyst exchanges
0executives
Key numbers — 37 extracted
rs,
1 Million
15.27 million
1.06 million
72%
2.08 billion
132
million
41%
59%
rs
15
15 million
rs
9
Guidance — 15 items
Business overview
opening
“During the Q1'FY26, the company sold more than 1.06 million meters, the highest ever in any quarter (72%) jump on yoy basis.”
Business overview
opening
“Expect business to stabilise over the next 2-3 quarters once the geopolitical situation and the trade war settle.”
Business Segments
opening
“in Crores 1550 1570 FY'24 FY'25 2000 1500 1000 500 0 400 300 200 100 0 Q1'FY 26 quarterly Revenue Rs.”
Business Segments
opening
“in Crores 389 385 395 Q1'FY25 Q4'FY25 Q1'FY26 2 Medical devices Q1'FY 26 2 Medical Devices market leadership: market leadership: Q1'FY 26 #1 #1 25 yr Market Leaders for Blood Glucose meters Market Leaders for BP Monitors of focused customer service Own manufacturing since 10 years 15m ISO 15 million Meters installed, repeat customers fully backward integrated supply chain All India Distribution and Service ISO-13485 Approved Facilities 2 Medical Devices”
Total revenue
opening
“in Crores 200 150 138 161 16%16% 100 50 0 Q1'FY25 Q1'FY26 FY'24 FY'25 500 400 300 200 100 0 2 Medical Devices glucometer revenue : glucometer revenue : no.”
Total revenue
opening
“of strips sold (lakh) 12 10 8 6 4 2 0 10.63 1400 1320 72%72% 1200 1171 13%13% 6.18 Q1'FY25 Q1'FY26 1000 800 600 400 200 0 Q1'FY25 Q1'FY26 140 120 100 80 60 40 20 0 Q1'FY 26 Annual Revenue Rs.”
Total revenue
opening
“in Crores 129 21%21% 107 Q1'FY25 Q1'FY26 2 Medical Devices glucometer Leadeship: glucometer Leadeship: Q1'FY 26 15.3 mn gluco meters sold Happy customer base 2.1 bn Gluco Strips sold Individual tests strips Cumulative YTD numbers 2 Medical Devices”
BP Monitor revenue
opening
“in Crores 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 3.37 3.17 6%6% Q1'FY25 Q1'FY26 30 25 20 15 10 5 0 26 24 7%7% Q1'FY25 Q1'FY26 2 Medical Devices”
Total Pharma revenue
opening
“in Crores 1074 1107 FY'24 FY'25 1200 1000 800 600 400 200 0 300 250 200 150 100 50 0 Q1'FY 26 quarterly Revenue Rs.”
Total Pharma revenue
opening
“in Crores 282 250 235 Q1'FY25 Q4'FY25 Q1'FY26 3 pHarma Business/API”
Risks & concerns — 2 flagged
There is pressure on margins due to low price realisation, increased input costs, and rising fixed costs.
— Business overview
Morepen - Sync r Log and track your key health metrics like blood glucose, blood pressure, weight and much more, effortlessly.
— Digital assets
Speaking time
2
1
1
1
1
1
1
1
1
1
Opening remarks
Business overview
Q1'FY 26 Strongest Quarter Ever in Glucometer Sales – 1 Million+ Units Sold! • • • • • With a solid 15.27 million diabetic patient customer base, the company continues to invest in acquiring new customers and installing new Glucometers. During the Q1'FY26, the company sold more than 1.06 million meters, the highest ever in any quarter (72%) jump on yoy basis. Proudly crosses a landmark of 2.08 billion test strips sold to date, with 132 million test strips sold in this quarter. Adding new products to the consumer basket to serve home medical device needs at affordable prices. Export market development continues with regular customer visits and international medical devices exhibitions. 1 Executive Summary
Business overview
Q1'FY 26 Strengthening Core APIs – Domestic Pivot Pays Off • • • • • Despite global headwinds, the company has managed to reinforce its market leadership in the key APIs. Strategic pivoting towards increased sales and marketing efforts in the domestic market to shield against the global uncertainties in the long term. Enhanced focus on long-term R&D and innovative product lines in the new chronic therapeutic categories. There is pressure on margins due to low price realisation, increased input costs, and rising fixed costs. Expect business to stabilise over the next 2-3 quarters once the geopolitical situation and the trade war settle. 1 Executive Summary
Business Segments
standAlone Q1'FY 26 Medical Devices Point of Care Pharma Business API+Rx 41% Share of Medical Devices 59% Share of Pharma Business 1 Executive Summary standalone revenue: standalone revenue: Annual Revenue Rs. in Crores Rs. in Crores 1550 1570 FY'24 FY'25 2000 1500 1000 500 0 400 300 200 100 0 Q1'FY 26 quarterly Revenue Rs. in Crores Rs. in Crores 389 385 395 Q1'FY25 Q4'FY25 Q1'FY26 2 Medical devices Q1'FY 26 2 Medical Devices market leadership: market leadership: Q1'FY 26 #1 #1 25 yr Market Leaders for Blood Glucose meters Market Leaders for BP Monitors of focused customer service Own manufacturing since 10 years 15m ISO 15 million Meters installed, repeat customers fully backward integrated supply chain All India Distribution and Service ISO-13485 Approved Facilities 2 Medical Devices
Top selling Products
Q1'FY 26 Blood Glucose meters BP Monitors Nebulisers 9Bt.f1' :0 Thermometers Ortho supports Stethoscope Pregnancy Kits 2 Medical Devices
Total revenue
Q1'FY 26 Annual Revenue Rs. in Crores Rs. in Crores 443 496 12%12% quarterly Revenue Rs. in Crores Rs. in Crores 200 150 138 161 16%16% 100 50 0 Q1'FY25 Q1'FY26 FY'24 FY'25 500 400 300 200 100 0 2 Medical Devices glucometer revenue : glucometer revenue : no. of Glucometers sold (lakh) no. of strips sold (lakh) 12 10 8 6 4 2 0 10.63 1400 1320 72%72% 1200 1171 13%13% 6.18 Q1'FY25 Q1'FY26 1000 800 600 400 200 0 Q1'FY25 Q1'FY26 140 120 100 80 60 40 20 0 Q1'FY 26 Annual Revenue Rs. in Crores Rs. in Crores 129 21%21% 107 Q1'FY25 Q1'FY26 2 Medical Devices glucometer Leadeship: glucometer Leadeship: Q1'FY 26 15.3 mn gluco meters sold Happy customer base 2.1 bn Gluco Strips sold Individual tests strips Cumulative YTD numbers 2 Medical Devices
BP Monitor revenue
Q1'FY 26 no. of BP meters sold (Lakhs) Annual Revenue Rs. in Crores Rs. in Crores 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 3.37 3.17 6%6% Q1'FY25 Q1'FY26 30 25 20 15 10 5 0 26 24 7%7% Q1'FY25 Q1'FY26 2 Medical Devices